Kisspeptin-10

Typical use cases

Dosing guidelines

Titration

No standardized titration is established. Research studies used fixed weight-based doses rather than escalating personal regimens; the extremely short half-life means effects are transient and dose-timing dependent. (Educational only — not dosing guidance.)

Reconstitution

Lyophilized powder is typically reconstituted with bacteriostatic or sterile water; a common research approach is 1–2 mL added to a 5 mg vial, swirled (not shaken) until fully dissolved. Concentration is chosen to make the intended measured volume convenient.

Injection sites

Subcutaneous injection into fatty tissue (abdomen, flank, or upper thigh) in community use; controlled clinical studies used intravenous bolus or infusion.

Storage & handling

Store lyophilized powder refrigerated (2–8°C) or frozen for long-term; once reconstituted, keep refrigerated (2–8°C) and use within several weeks. Protect from light and avoid repeated freeze–thaw cycles.

Side effects

• Injection-site reaction (redness, irritation) Mild · Common
• Transient flushing or warmth Mild · Uncommon
• Headache Mild · Uncommon
• Nausea Mild · Uncommon
• Transient hormonal fluctuation (LH/FSH/testosterone shifts) Mild · Common
• Hypersensitivity/allergic reaction Moderate · Rare

Research summary

Kisspeptin-10 (KP-10) is the C-terminal decapeptide of kisspeptin-54, encoded by the KISS1 gene, and acts as a potent agonist at the KISS1R (GPR54) receptor on hypothalamic GnRH neurons, signaling through Gq/11–phospholipase C to mobilize intracellular calcium and trigger GnRH-dependent gonadotropin secretion. Controlled human studies are the strongest part of its evidence base: intravenous bolus doses (0.01–3.0 µg/kg) produced rapid, dose-dependent rises in serum LH in men, with maximal effect near 1 µg/kg, and continuous infusion (e.g., 1.5 µg/kg/h) increased LH pulse frequency, demonstrating its value as a tool to probe pulsatile reproductive physiology (George et al., JCEM 2011). A notable finding is marked sexual dimorphism: men respond robustly across a range of doses, whereas follicular-phase women showed essentially no gonadotropin response even at substantially higher doses, with responsiveness emerging only in the preovulatory phase (Jayasena et al., JCEM 2011). Much of the human sexual/behavioral and neuroimaging work (limbic activation to sexual stimuli, increased penile tumescence in men with hypoactive sexual desire disorder) was conducted with the longer kisspeptin-54, not KP-10 itself, so extrapolation to KP-10 is indirect. Across published trials KP-10 was generally well tolerated with stable blood pressure and heart rate and no serious adverse events reported, but these were small, short-duration academic studies in selected populations. A major limitation is KP-10's very short plasma half-life (~4 minutes IV versus ~32 minutes for KP-54), which constrains practical use and has motivated development of longer-acting analogs; long-term safety, repeated-dosing, and any non-research "protocol" use remain uncharacterized.

Key references

• https://academic.oup.com/jcem/article/96/8/E1228/2833644
• https://pmc.ncbi.nlm.nih.gov/articles/PMC3232613/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC5413024/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC4678402/
• https://pubmed.ncbi.nlm.nih.gov/36735255/

Related compounds